A Phase I,Randomized,Placebo-Controlled,3-Day,Ascending-Dose Study of Gs-9451,An Ns3/4A Protease Inhibitor,in Genotype 1 Hepatitis C Patients

Abstract

Background

GS-9451 is a novel inhibitor of the HCV NS3/4A protease and demonstrates potent in vitro suppression of HCV genotype 1 replicons.

Methods

The safety, pharmacokinetics and antiviral efficacy of GS-9451 were evaluated in a Phase I study in treatment-naive, HCV genotype-1-infected patients. Patients were randomized to 3 days of once-daily dosing with placebo (n=8) or GS-9451 60 mg (n=8 genotype 1a), 200 mg (n=8 genotype 1a; n=8 genotype 1b) or 400 mg (n=9 genotype 1a). Plasma samples were collected up to and on day 14 for pharmacokinetic evaluation, serum HCV RNA quantitation and NS3 sequencing.

Results

No patients interrupted or discontinued dosing because of an adverse event. The median (range) maximal HCV RNA reductions from baseline were -0.88 (-1.24– -0.64), -3.19 (-3.31– -2.94) and -3.64 (-4.08– -3.54) log₁₀ IU/ml in genotype 1a patients receiving 60, 200 and 400 mg/day GS-9451, respectively, and -3.48 (-3.54– -3.03) log₁₀ IU/ml in genotype 1b patients receiving GS-9451 200 mg/day. Median half-life ranged from 14 to 17 h. Day 3 mean concentration at the end of dosing interval was 5.5- and 17-fold above protein-binding adjusted mean 50% effective inhibitory concentration in 200 mg and 400 mg cohorts, respectively. No resistance mutations were detected with GS-9451 60 mg/day. In the 200 mg/day or 400 mg/day groups, predominant mutations were NS3 R155 (R155K) in genotype 1a patients and D168 (D168E, D168V and D168G) in genotype 1b patients.

Conclusions

GS-9451 was well-tolerated. During 3 days of monotherapy, GS-9451 200 mg/day or 400 mg/day demonstrated potent antiviral activity in both HCV genotype 1a- and 1b-infected patients. GS-9451 is currently being evaluated in combination regimens with and without pegylated interferon-α.

References

Kwo

P.Y.

, Lawitz

E.J.

, McCone

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 2010; 376: 705–716.

Poordad

, McCone

Jr. , Bacon

B.R.

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–1206.

Jacobson

I.M.

, McHutchison

J.G.

, Dusheiko

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–2416.

McHutchison

J.G.

, Everson

G.T.

, Gordon

S.C.

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827–1838.

Hézode

, Forestier

, Dusheiko

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839–1850.

Bacon

B.R.

, Gordon

S.C.

, Lawitz

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207–1217.

Fried

M.W.

, Shiffman

M.L.

, Reddy

K.R.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

McHutchison

J.G.

, Lawitz

E.J.

, Shiffman

M.L.

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580–593.

Manns

M.P.

, McHutchison

J.G.

, Gordon

S.C.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.

10.

Hadziyannis

S.J.

, Sette

Jr. , Morgan

T.R.

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–355.

11.

McHutchison

J.G.

, Manns

M.P.

, Muir

A.J.

Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292–1303.

12.

Wilby

K.J.

, Greanya

E.D.

, Ford

J-A.E.

, Yoshida

E.M.

, Partovi

A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11: 179–185.

13.

Seden

, Back

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS. 2011; 6: 514–526.

14.

Chary

, Holodniy

Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Rev Recent Clin Trials 2010; 5: 158–173.

15.

Asselah

, Marcellin

New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int 2011; 31 Suppl 1: 68–77.

16.

Gane

Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int 2011; 31 Suppl 1: 62–67.

17.

Corsa

, Robinson

, Yang

Preclinical properties of the novel HCV NS3 protease inhibitor GS-9451. J Hepatol 2011; 54 Suppl 1: S313.

18.

Reesink

H.W.

, Zeuzem

, Weegink

C.J.

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997–1002.

19.

Sarrazin

, Rouzier

, Wagner

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270–1278.

20.

Manns

, Reesink

, Berg

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011; 16: 1021–1033.

21.

Kwo

P.Y.

Phase III results in genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver Int 2012; 32 Suppl 1: 39–43.

22.

Kieffer

T.L.

, Sarrazin

, Miller

J.S.

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631–639.

23.

Hazuda

, Ogert

, Howe

Analysis of resistance associated variants by HCV genotype 1 subtype (1a/1b) in Phase 3 (SPRINT-2/RESPOND-2) boceprevir plus standard of care clinical trials. 6th IAS Conference International AIDS Society. 17–20 July 2011, Rome, Italy. Abstract WELBX04.

24.

Dvory-Sobol

, Schwartz

, Han

, Worth

, Rajyaguru

, Svarovskaia

E.S.

In-vitro fitness and resistance analyses of NS3 mutants detected by population and deep sequencing in HCV patients from Phase 1 studies of GS-9451 and GS-9256. J Hepatol 2012; 56 Suppl 2: S465.

25.

Tong

, Mwangi

, Roy

In vitro studies on the potential for the hepatitis C virus protease inhibitors GS-9256 and GS-9451 to affect bilirubin elimination. J Hepatol 2011; 54 Suppl 1: S487.

26.

Manns

M.P.

, Bourlière

, Benhamou

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011; 54: 1114–1122.

27.

Sane

, Podila

, Mathur

Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335. J Hepatol 2011; 54 Suppl 1: S488.

28.

Fried

M.W.

, Buti

, Dore

G.J.

Efficacy and safety of TMC435 in combination with peginterferon α-2a and ribavirin in treatment-naive genotype-1 HCV patients: 24-week interim results from the PILLAR Study. Hepatology 2010; 52 Suppl 1: 107A.

29.

INCIVEKTM (telaprevir) Film coated tablets 2011. Vertex Pharmaceuticals Incorporated. Cambridge, MA, USA.

30.

Zeuzem

, Asselah

, Angus

Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 2047–2055.